Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative

Abstract The increased incidence of antibiotic resistant ‘superbugs’ has amplified the use of broad spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Melanie L. Hutton, Bliss A. Cunningham, Kate E. Mackin, Shelley A. Lyon, Meagan L. James, Julian I. Rood, Dena Lyras
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/287f80b5616c443694627a600e1f3867
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:287f80b5616c443694627a600e1f3867
record_format	dspace
spelling	oai:doaj.org-article:287f80b5616c443694627a600e1f38672021-12-02T12:32:34ZBovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative10.1038/s41598-017-03982-52045-2322https://doaj.org/article/287f80b5616c443694627a600e1f38672017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03982-5https://doaj.org/toc/2045-2322Abstract The increased incidence of antibiotic resistant ‘superbugs’ has amplified the use of broad spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridium difficile. Paradoxically, treatment of C. difficile infections (CDI) also involves antibiotic use, leaving patients susceptible to re-infection. This serious health threat has led to an urgent call for the development of new therapeutics to reduce or replace the use of antibiotics to treat bacterial infections. To address this need, we have developed colostrum-derived antibodies for the prevention and treatment of CDI. Pregnant cows were immunised to generate hyperimmune bovine colostrum (HBC) containing antibodies that target essential C. difficile virulence components, specifically, spores, vegetative cells and toxin B (TcdB). Mouse infection and relapse models were used to compare the capacity of HBC to prevent or treat primary CDI as well as prevent recurrence. Administration of TcdB-specific colostrum alone, or in combination with spore or vegetative cell-targeted colostrum, prevents and treats C. difficile disease in mice and reduces disease recurrence by 67%. C. difficile-specific colostrum should be re-considered as an immunotherapeutic for the prevention or treatment of primary or recurrent CDI.Melanie L. HuttonBliss A. CunninghamKate E. MackinShelley A. LyonMeagan L. JamesJulian I. RoodDena LyrasNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Melanie L. Hutton Bliss A. Cunningham Kate E. Mackin Shelley A. Lyon Meagan L. James Julian I. Rood Dena Lyras Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
description	Abstract The increased incidence of antibiotic resistant ‘superbugs’ has amplified the use of broad spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridium difficile. Paradoxically, treatment of C. difficile infections (CDI) also involves antibiotic use, leaving patients susceptible to re-infection. This serious health threat has led to an urgent call for the development of new therapeutics to reduce or replace the use of antibiotics to treat bacterial infections. To address this need, we have developed colostrum-derived antibodies for the prevention and treatment of CDI. Pregnant cows were immunised to generate hyperimmune bovine colostrum (HBC) containing antibodies that target essential C. difficile virulence components, specifically, spores, vegetative cells and toxin B (TcdB). Mouse infection and relapse models were used to compare the capacity of HBC to prevent or treat primary CDI as well as prevent recurrence. Administration of TcdB-specific colostrum alone, or in combination with spore or vegetative cell-targeted colostrum, prevents and treats C. difficile disease in mice and reduces disease recurrence by 67%. C. difficile-specific colostrum should be re-considered as an immunotherapeutic for the prevention or treatment of primary or recurrent CDI.
format	article
author	Melanie L. Hutton Bliss A. Cunningham Kate E. Mackin Shelley A. Lyon Meagan L. James Julian I. Rood Dena Lyras
author_facet	Melanie L. Hutton Bliss A. Cunningham Kate E. Mackin Shelley A. Lyon Meagan L. James Julian I. Rood Dena Lyras
author_sort	Melanie L. Hutton
title	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
title_short	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
title_full	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
title_fullStr	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
title_full_unstemmed	Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative
title_sort	bovine antibodies targeting primary and recurrent clostridium difficile disease are a potent antibiotic alternative
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/287f80b5616c443694627a600e1f3867
work_keys_str_mv	AT melanielhutton bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT blissacunningham bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT kateemackin bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT shelleyalyon bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT meaganljames bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT julianirood bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative AT denalyras bovineantibodiestargetingprimaryandrecurrentclostridiumdifficilediseaseareapotentantibioticalternative
_version_	1718394027065212928

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative

Ejemplares similares